This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma

65 views
September 27, 2024
Comments 0
Login to view comments. Click here to Login